Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors

PLoS Genetics

Volumn 7, Issue 10, 2011, Pages

  Moore, Lee E ^a   Nickerson, Michael L ^b   Brennan, Paul ^c   Toro, Jorge R ^a   Jaeger, Erich ^d   Rinsky, Jessica ^a   Han, Summer S ^a   Zaridze, David ^e   Matveev, Vsevolod ^e   Janout, Vladimir ^f   Kollarova, Hellena ^f   Bencko, Vladimir ^g   Navratilova, Marie ^h   Szeszenia Dabrowska, Neonilia ⁱ   Mates, Dana ^j   Schmidt, Laura S ^a,k   Lenz, Petra ^k   Karami, Sara ^a   Linehan, W Marston ^a   Merino, Maria ^k   Chanock, Stephen ^a   Boffetta, Paolo ^b,l,m   Chow, Wong Ho ^a   Waldman, Frederic M ^d   Rothman, Nathaniel ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

ⁱ NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^j NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^k SAIC FREDERICK INC   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m International Cancer Prevention Research Institute   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRICHLOROETHYLENE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; DIETARY INTAKE; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; EXON; FRUIT INTAKE; GENE; GENE DELETION; GENE INACTIVATION; GENE INSERTION SEQUENCE; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETIC VARIABILITY; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; OCCUPATIONAL EXPOSURE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPORADIC CLEAR CELL RENAL CANCER; VON HIPPEL LINDAU GENE; ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; CPG ISLAND; FEMALE; GENE SILENCING; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR;

ADULT; AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 80055069795     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002312     Document Type: Article

References (55)

1. Linehan WM, Walther MM, Zbar B, (2003) The genetic basis of cancer of the kidney. J Urol 170: 2163-2172.
2. Garcia-Closas M, Vermeulen R, Sherman M, Moore L, Smith M, et al. (2006) Application of biomarkers in cancer epidemiology. In: Schotenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 3rd ed New York: Oxford University Press pp. 70-88.
3. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor-suppressor gene. Science 260: 1317-1320.
4. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, et al. (2008) Tissue-based research in kidney cancer: Current challenges and future directions. Clin Cancer Res 14: 3699-3705.
5. Chow WH, Devesa SS, (2008) Contemporary epidemiology of renal cell cancer. Cancer J 14: 288-301.
6. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, et al. (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14: 4726-4734.
7. Maxwell PH, Weisener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-75.
8. Kaelin WG Jr, (2002) Molecular basis of the VHL heteditary cancer syndropme. Nat Rev Cancer 2: 673-82.
9. Hemminki K, Jiang YW, Ma X, Yang K, Egevad L, et al. (2002) Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis 23: 809-815.
10. van Dijk BAC, Schouten LJ, Oosterwijk E, Hulsbergen-van de Kaa CA, Kiemeney L, et al. (2006) Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Br J Cancer 95: 374-377.
11. Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, et al. (1999) Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 91: 854-861.
12. Bruning T, Weirich G, Hornauer MA, Hofler H, Brauch H, (1997) Renal cell carcinomas in trichloroethene (TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau (VHL) tumour suppressor gene. Arch Toxicol 71: 332-5.
13. Young AC, Craven RA, Cohen D, Taylor C, Booth C, et al. (2009) Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15: 7582-7592.
14. Stram DO, (2004) Tag SNP selection for association studies. Gen Epidemiol 27: 365-74.
15. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011.
16. Van Dijk BA, Schouten LJ, Hulsbergen-van de Kaa CA, van Houwelingen KP, Schalken JA, et al. (2002) Risk factors, genetic predisposition and mutations in the VHL gene in sporadic renal cell carcinoma: The Netherlands Cohort Study. IARC Sci Publ 156: 509-10.
17. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, et al. (2007) MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 28: 1985-1990.
18. Hawkins NJ, Lee JHF, Wong JJL, Kwok CT, Ward RL, et al. (2009) MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol 22: 1588-1599.
19. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, et al. (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129: 879-890.
20. Chen HP, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, et al. (2007) Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 120: 1684-1688.
21. Hitchins MP, Ward RL, (2009) Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 46: 793-802.
22. Murrell A, Heeson S, Cooper WN, Douglas E, Apostolidou S, et al. (2004) An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype. Hum Mol Genet 13: 247-255.
23. Richards EJ, (2006) Inherited epigenetic variation-revisiting soft inheritance. Nat Rev Genet 7: 395-4000.
24. Oyer JA, Chu A, Brar S, Turker MS, (2009) Aberrant epigenetic silencing is triggered by a transient reduction in gene expression. PLoS ONE 4: e4832 doi:10.1371/journal.pone.0004832.
25. Liu W, He L, Ramirez J, Krishnaswamy S, Kanteti R, et al. (2011) Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cel lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 71: 2423-7.
26. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, et al. (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34: 58-68.
27. Smits KM, Schouten LJ, van Dijk BAC, de Kaa C, Wouters KAD, et al. (2008) Genetic and epigenetic alterations in the von Hippel-Lindau gene: The influence on renal cancer prognosis. Clin Cancer Res 14: 782-787.
28. Suzuki H, Ueda T, Komiya A, Okano T, Isaka S, et al. (1997) Mutational state of von Hippel-Lindau and adenomatous polyposis coli genes in renal tumors. Oncology 54: 252-257.
29. Hamano K, Esumi M, Igarashi H, Chino K, Mochida J, et al. (2002) Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. J Urol 167: 713-717.
30. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, et al. (2002) VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196: 186-93.
31. van Houwelingen KP, van Dijk BAC, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJM, et al. (2005) Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study. BMC Cancer 5: 57.
32. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, et al. (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14: 435-46.
33. Atkins DJ, Gingert C, Justenhoven C, Schmahl GE, Bonato MS, et al. (2005) Concomitant deregulation of HIF1 alpha and cell cycle proteins in VHL-mutated renal cell carcinomas. Virchows Arch 447: 634-642.
34. Petrella BL, Brinckerhoff CE, (2009) PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinoma. Cancer Biol Ther 8: 1389-1401.
35. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, et al. (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123: 395-400.
36. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, et al. (2009) CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 8: 31.
37. Golshayan AR, Brick AJ, Choueiri TK, (2008) Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 4: 85-92.
38. Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, et al. (2009) Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 101: 1417-1424.
39. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, et al. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. Journal Natl Cancer Inst 94: 1569-1575.
40. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim, et al. (2005) Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13: 859-864.
41. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, et al. (2006) Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98: 756-762.
42. Moore LE, Boffetta P, Karami S, Brennan P, Stwart PS, et al. (2010) Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. Cancer Res 70 (16): 6527-36.
43. Charbotel B, Gad S, Caiola D, Beroud C, Fevotte J, et al. (2007) Trichloroethylene exposure and somatic mutations of the VHL gene in patients with Renal Cell Carcinoma. J Occup Med Toxicol 2: 13.
44. Curado MP, Edwards B, Shin HR, Ferlay J, Heanue M, et al. (2008) Cancer Incidence in Five Continents, Volume IX IARC Scientific Publications.
45. Brennan P, van der Hel O, Moore LE, Zaridze D, Matveev V, et al. (2008) Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer 99: 1912-1915.
46. Hung RJ, Moore L, Boffetta P, Feng BJ, Toro JR, et al. (2007) Family history and the risk of kidney cancer: A multicenter case-control study in Central Europe. Cancer Epidemiol Biomarkers Prev 16: 1287-1290.
47. Hsu CC, Chow WH, Boffetta P, Moore L, Zaridze D, et al. (2007) Dietary risk factors for kidney cancer in Eastern and Central Europe. Am J Epidemiol 166: 62-70.
48. Hodgson G, Hager GH, Volik S, Wernick M, Moore D, et al. (2001) Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 29 (4): 459-64.
49. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, et al. (2002) Array-based comparative genomic hybridizaiont for the differential diagnosis of renal cell cancer. Cancer Res 62 (4): 957-60.
50. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, et al. (1998) High resloultion analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20 (2): 207-211.
51. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albsertson DG, et al. (2002) Fully automatic quantification of microarray impage data. Genome Res 12: 325-332.
52. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, et al. (2006) Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 18:6: 96.
53. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA, (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70: 425-434.
54. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, et al. (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55: 56-65.
55. Schaid DJ, (2004) Evaluating associations of haplotypes with traits. Genet Epidemiol 27: 348-364.